Investor Relations
Investing in the Future of Cancer Treatment
Embio Medical is advancing proprietary catheter-based electroporation technologies to address a significant unmet medical need. We welcome conversations with investors who share our vision for transforming cancer care.
Addressing a Significant Unmet Medical Need
The market for advanced cancer treatment technologies is large and growing, driven by the urgent need for effective therapies for difficult-to-treat cancers.
60,000+
New Pancreatic Cancer Cases (US/yr)
New US pancreatic cancer diagnoses annually, with limited treatment options.
$2B+
Tumour Ablation Devices Market
Growing market for tumour ablation technologies worldwide.
13%
5-Year Survival Rate
Pancreatic cancer 5-year survival rate as of January 2026, highlighting the urgent unmet need.
Our Journey
Company Founded
Embio Medical established with a mission to develop advanced electroporation-based treatments for hard-to-treat cancers.
Core Technology Development
Initial development and validation of the proprietary electroporation catheter platform technology.
DuCath Platform Prototype
Completion of the first DuCath dual-channel catheter prototype and initiation of preclinical studies.
PonCath Platform Development
Development of the PonCath endoscopic catheter platform for bile duct and pancreatic duct applications.
Preclinical Milestones
Completion of key preclinical validation studies and preparation for regulatory engagement.
Strategic Growth Phase
Advancing toward clinical readiness and establishing partnerships with leading medical institutions.
Interested in Investing?
We welcome inquiries from investors and potential partners. Reach out to learn more about our technology, pipeline, and investment opportunities.